Opportunity

           Auxagen plans to complete SBIR phase II studies on wound treatment and file an IND in 2012 or early 2013. The strategies for clinical trials and commercialization of the TGF-β antagonist products are to seek partnerships with large pharmaceutical companies and/or biotech companies and/or investors for clinical trials. Auxagen is currently seeking partners and licensees to develop the TGF-β receptor antagonists into commercial products.